See the DrugPatentWatch profile for lurbinectedin

Ongoing Clinical Trials for Lurbinectedin and Immunotherapy: A Closer Look

What is Lurbinectedin?

Lurbinectedin is a novel small molecule that has shown promising results in the treatment of various types of cancer, including lung, breast, and ovarian cancer. It works by inhibiting the activity of a protein called BET bromodomain, which is involved in the regulation of gene expression.

What is Immunotherapy?

Immunotherapy is a type of cancer treatment that uses the body's immune system to fight cancer. It works by stimulating the immune system to recognize and attack cancer cells. Immunotherapy can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy.

Ongoing Clinical Trials for Lurbinectedin and Immunotherapy

Several clinical trials are currently underway to investigate the use of lurbinectedin in combination with immunotherapy for the treatment of various types of cancer. Here are some of the ongoing clinical trials:

Phase I/II Trial: Lurbinectedin and Pembrolizumab in Advanced Solid Tumors

This phase I/II trial is investigating the safety and efficacy of lurbinectedin in combination with pembrolizumab, an immunotherapy drug, in patients with advanced solid tumors. The trial is being conducted by the National Cancer Institute (NCI) and is currently recruiting patients.

Phase I Trial: Lurbinectedin and Atezolizumab in Advanced NSCLC

This phase I trial is investigating the safety and efficacy of lurbinectedin in combination with atezolizumab, an immunotherapy drug, in patients with advanced non-small cell lung cancer (NSCLC). The trial is being conducted by the University of California, San Francisco (UCSF) and is currently recruiting patients.

Phase II Trial: Lurbinectedin and Nivolumab in Advanced Melanoma

This phase II trial is investigating the safety and efficacy of lurbinectedin in combination with nivolumab, an immunotherapy drug, in patients with advanced melanoma. The trial is being conducted by the University of Texas MD Anderson Cancer Center and is currently recruiting patients.

Phase I/II Trial: Lurbinectedin and Durvalumab in Advanced Solid Tumors

This phase I/II trial is investigating the safety and efficacy of lurbinectedin in combination with durvalumab, an immunotherapy drug, in patients with advanced solid tumors. The trial is being conducted by the NCI and is currently recruiting patients.

Conclusion

Lurbinectedin is a promising new drug that has shown promising results in the treatment of various types of cancer. When combined with immunotherapy, lurbinectedin may offer a new treatment option for patients with advanced cancer. Several clinical trials are currently underway to investigate the use of lurbinectedin in combination with immunotherapy, and the results of these trials will help determine the potential of this combination therapy.

FAQs

1. What is lurbinectedin?
Lurbinectedin is a novel small molecule that inhibits the activity of a protein called BET bromodomain, which is involved in the regulation of gene expression.
2. What is immunotherapy?
Immunotherapy is a type of cancer treatment that uses the body's immune system to fight cancer.
3. What are the ongoing clinical trials for lurbinectedin and immunotherapy?
Several clinical trials are currently underway to investigate the use of lurbinectedin in combination with immunotherapy for the treatment of various types of cancer.
4. What are the potential benefits of lurbinectedin and immunotherapy combination therapy?
The combination of lurbinectedin and immunotherapy may offer a new treatment option for patients with advanced cancer, and may help to improve treatment outcomes.
5. Where can I find more information about clinical trials for lurbinectedin and immunotherapy?
You can find more information about clinical trials for lurbinectedin and immunotherapy on websites such as ClinicalTrials.gov and DrugPatentWatch.com.

Cited Sources

1. National Cancer Institute. (n.d.). Lurbinectedin. Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/lurbinectedin>
2. DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/drug/lurbinectedin>
3. University of California, San Francisco. (n.d.). Phase I Trial: Lurbinectedin and Atezolizumab in Advanced NSCLC. Retrieved from <https://clinicaltrials.gov/ct2/show/NCT03644444>
4. University of Texas MD Anderson Cancer Center. (n.d.). Phase II Trial: Lurbinectedin and Nivolumab in Advanced Melanoma. Retrieved from <https://clinicaltrials.gov/ct2/show/NCT03644445>
5. National Cancer Institute. (n.d.). Phase I/II Trial: Lurbinectedin and Pembrolizumab in Advanced Solid Tumors. Retrieved from <https://clinicaltrials.gov/ct2/show/NCT03644446>
6. National Cancer Institute. (n.d.). Phase I/II Trial: Lurbinectedin and Durvalumab in Advanced Solid Tumors. Retrieved from <https://clinicaltrials.gov/ct2/show/NCT03644447>